Phase III cancer vaccine trial meets primary endpoint

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The primary endpoint was met in a predefined step-1 analysis of a phase III trial in non-small cell lung cancer patients treated with Tedopi, a neoepitope cancer vaccine.

Data showed a 12 month-survival rate of 46% for patients treated with Tedopi versus 36% for patients in the chemotherapy control arm. Enrollment in the Step-2 portion of the phase III trial have been stopped due to concerns over COVID-19.

Instead, there will be further analysis of step-1 data in parallel with discussions with regulatory agencies on a pathway to approval.

Tedopi is being developed in a phase 3 trial in NSCLC for patients who have failed to respond on PD1/PDL1 checkpoint inhibitor treatments, the current standard of care. About 30% of NSCLC patients don’t respond to checkpoint inhibitors and this patient population lacks approved treatment options. Tedopi is also currently being explored in a phase II trial in pancreatic cancer.

Table of Contents

YOU MAY BE INTERESTED IN

Patients with metastatic colorectal cancer harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies Braftovi(encorafenib) and Erbitux(cetuximab) plus a mFOLFOX6 chemotherapy regimen, according to results from the phase III BREAKWATER trial led by researchers at the University of Texas MD Anderson Cancer Center.
Bristol Myers Squibb announced results of an analysis from the three-arm phase III CheckMate-8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo monotherapy across all lines of therapy, including first-line, for the treatment of microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. At a median follow-up of 47 months, Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in the dual-primary endpoint of progression-free survival as assessed by Blinded Independent Central Review versus Opdivo monotherapy (HR 0.62; 95% CI 0.48–0.81; P = 0.0003).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login